Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 2/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118519 | 1.00 | CCKBR (0.42) | CCKBRHTR5ABCHEHTR2BHRH2 | |
| SCHEMBL12141050 | 1.00 | CCKBR (0.42) | CCKBRHTR5ABCHEHTR2BHRH2 | |
| Fluorobenzene SCHEMBL27513190 | 0.90 | CCKBR (0.40) | CCKBRHTR5ABCHEHTR2BHRH2 | |
| Anisole SCHEMBL27512824 | 0.87 | PAX8 (0.45) | CCKBRPAX8 | |
| SCHEMBL8261364 | 0.85 | HTR5A (0.41) | CCKBRHTR5ABCHEHTR2BHRH2 | |
| SCHEMBL7074697 | 0.82 | BCHE (0.48) | CCKBRHTR5ABCHE | |
| SCHEMBL6648615 | 0.81 | BCHE (0.50) | CCKBRHTR5ABCHEHTR2C | |
| SCHEMBL8523648 | 0.80 | BCHE (0.47) | CCKBRHTR5ABCHE | |
| SCHEMBL12956451 | 0.80 | CCKBR (0.38) | CCKBRBCHEHTR2BHRH2OPRM1 | |
| SCHEMBL1030313 | 0.80 | SLC6A4 (0.40) | CCKBRBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225563-A2 | SELECTIVE SIGMA-2 RECEPTOR LIGANDS AS MODULATORS OF TMEM97 | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023163971-A1 | METHODS OF TREATING COVID-RELATED DISORDERS | ATHIRA PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-3322417-B1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | UNIV TEXAS (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023093834-A1 | PYRROLIDINE ANTIVIRAL COMPOUND | 先声再明医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | ISR IMMUNE SYSTEM REGULATION HOLDING AB PUBL (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11434258-B2 | Compounds (immunorhelins) | ISR Immune System Regulation Holding AB (SE) | 2022-09-06 | — | — | US | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | NuCana plc (GB) | 2021-06-22 | — | — | US | disclosed |
| US-10919882-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2021-02-16 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053193-A2 | UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053725-A2 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-02-22 | — | — | US | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176229-B2 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION (US) | 2007-02-13 | — | — | US | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | CCKBR 4611/4885HTR5A 2320/4885BCHE 3114/4885 |
| US-20230118205-A1 | NOVEL COMPOUNDS (IMMUNORHELINS) | GNRHR, FSHR, LHCGR | CCKBR 138/4885HTR5A 546/4885BCHE 2459/4885 |
| US-10919882-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | CCKBR 541/4885HTR5A 4021/4885BCHE 605/4885 |
| US-11040997-B2 | Process for preparing nucleoside prodrugs | PNP, TYMP, SLC29A1 | CCKBR 2987/4885HTR5A 4088/4885BCHE 633/4885 |
| US-20070043033-A1 | Unsolvated benzodiazepine compositions and methods | GABRA5, GABRA3, GABRA6 | CCKBR 429/4885HTR5A 74/4885BCHE 832/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | CCKBR 18/4885HTR5A 320/4885BCHE 2976/4885 |
| US-20070111994-A1 | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties | BAD, GABRA5, GABRB1 | CCKBR 615/4885HTR5A 149/4885BCHE 4315/4885 |
| US-11434258-B2 | Compounds (immunorhelins) | GNRHR, FSHR, LHCGR | CCKBR 96/4885HTR5A 406/4885BCHE 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.